Canlyniadau Chwilio - Nurmohamed, M

Prevention of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty: a continuing matter of debate gan NURMOHAMED, M, DIJKMANS, B

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous? gan NURMOHAMED, M, LEMS, W, DIJKMANS, B

Cael y testun llawn Cael y testun llawn

Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice gan Neven, N, Vis, M, Voskuyl, A, Wolbink, G, Nurmohamed, M, Dijkmans, B, Lems, W

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Neutrophil activation identifies patients with active polyarticular gout gan Vedder, D., Gerritsen, M., Duvvuri, B., van Vollenhoven, R. F., Nurmohamed, M. T., Lood, C.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study gan Wiegel, J., Seppen, B. F., ter Wee, M. M., Nurmohamed, M. T., Boers, M., Bos, W. H.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure. gan Gianese, F, Nurmohamed, M T, Imbimbo, B P, Büller, H R, Berckmans, R J, Ten Cate, J W

Cael y testun llawn Cael y testun llawn

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis gan Wolbink, G, Voskuyl, A, Lems, W, de Groot, E, Nurmohamed, M, Tak, P, Dijkmans, B, Aarden, L

Cael y testun llawn Cael y testun llawn Cael y testun llawn

High levels of human anti‐human antibodies to adalimumab in a patient not responding to adalimumab treatment gan Bartelds, G M, Wolbink, G J, Stapel, S, Aarden, L, Lems, W F, Dijkmans, B A C, Nurmohamed, M T

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Antibodies against human 60 kDa heat shock protein are not associated with cardiovascular disease in patients with rheumatoid arthritis gan van Halm, V P, Slot, M C, Nurmohamed, M T, Tervaert, J W Cohen, Dijkmans, B A C, Voskuyl, A E

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis gan Boers, M, Nurmohamed, M, Doelman, C, Lard, L, Verhoeven, A, Voskuyl, A, Huizinga, T, van de Stadt, R J, Dijkmans, B, van der Linden, S.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study gan van den Hoek, J., Boshuizen, H. C., Roorda, L. D., Tijhuis, G. J., Nurmohamed, M. T., van den Bos, G. A. M., Dekker, J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Aortic root diameter is associated with HLA-B27: identifying the patient with ankylosing spondylitis at risk for aortic valve regurgitation gan Baniaamam, M., Heslinga, S. C., Konings, T. C., Handoko, M. L., Kamp, O., van Halm, V. P., van der Horst-Bruinsma, I. E., Nurmohamed, M. T.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis gan van Denderen, J C, van der Paardt, M, Nurmohamed, M, de Ryck, Y M M A, Dijkmans, B, van der Horst-Bru..., I E

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Statin therapy might be beneficial for patients with ankylosing spondylitis gan van Denderen, J C, Peters, M J L, van Halm, V P, van der Horst‐Bruinsma, I E, Dijkmans, B A C, Nurmohamed, M T

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis gan Klaasen, R., Herenius, M M J, Wijbrandts, C A, de Jager, W, van Tuyl, L H, Nurmohamed, M T, Prakken, B J, Gerlag, D M, Tak, P P

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up gan Vogelzang, E. H., Hebing, R. C. F., Nurmohamed, M. T., van Kuijk, A. W. R., Kruijff, J. W. F., l’Ami, M. J., Krieckaert, C. L. M., Wolbink, G.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Implicit and explicit attitudes towards disease-modifying antirheumatic drugs as possible target for improving medication adherence gan van Heuckelum, M., Linn, A. J., Vandeberg, L., Hebing, R. C. F., van Dijk, L., Vervloet, M., Flendrie, M., Nurmohamed, M. T., van Dulmen, S., van den Bemt, B. J. F., van den Ende, C. H. M.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis gan van den Oever, I. A. M., Baniaamam, M., Simsek, S., Raterman, H. G., van Denderen, J. C., van Eijk, I. C., Peters, M. J. L., van der Horst-Bruinsma, I. E., Smulders, Y. M., Nurmohamed, M. T.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid a... gan Lucassen, M. J. J., ter Wee, M. M., den Uyl, D., Konijn, N. P. C., Nurmohamed, M. T., Voskuyl, A. E., van Schaardenburg, D., Kerstens, P. J. S. M., Bultink, I. E. M., Boers, M., Lems, W. F.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis gan Peters, M J L, Vis, M, van Halm, V P, Wolbink, G J, Voskuyl, A E, Lems, W F, Dijkmans, B A C, Twisk, J W R, de Koning, M H M T, van de Stadt, R J, Nurmohamed, M T

Cael y testun llawn Cael y testun llawn Cael y testun llawn